Trailing-twelve-month (TTM) revenue is $6.28 Billion with a year-over-year growth of +2.18%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,708,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-07 |
| Q4 FY2025Period ended 2025-12-31 | $1,556,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $1,398,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $1,622,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $6,284,000,000 |
Current P/S: $2,256,496,884 market capitalization ÷ $6,284,000,000 TTM revenue = 0.36x.
Market capitalization source: FMP quote. Quote observed 2026-10-05T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.62B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:50:42.242Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Accident and Health Insurance Product Line | $13M | $10M | $10M | $7M | $21M | $18M |
| Investment Product | $3.0B | $3.3B | $2.9B |
$6.28B
$6.28 Billion
+2.18%
vs. $6.15B a year ago (TTM)
(5.56%)
5 Year compound annual growth rate
1 Year
+2.18%
3 Year
+25.89%
5 Year
(5.56%)
10 Year
+0.11%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $6.21B | +$1.84B | +42.16% |
| 2024 | $4.37B | +$419.00M | +10.61% |
| 2023 | $3.95B | ($2.68B) | (40.42%) |
| 2022 | $6.63B | +$3.04B | +84.94% |
| 2021 | $3.58B | ($4.68B) | (56.63%) |
| 2020 |
TTM Growth
+2.18%
3-Year CAGR
+25.89%
5-Year CAGR
(5.56%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
| $2.4B |
| $2.3B |
| Life Insurance Product Line | $1.6B | $1.5B | $1.4B | $1.3B | $1.0B | $1.1B |
|---|
| $8.27B |
| +$1.94B |
| +30.65% |
| 2019 | $6.33B | ($2.34B) | (27.00%) |
| 2018 | $8.67B | +$1.82B | +26.67% |
| 2017 | $6.84B | +$3.78B | +123.67% |
| 2016 | $3.06B | ($5.83B) | (65.59%) |
